No price history available.
Key financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 0 | 0 | 0 | 0 | 0 | 0 | N/A | N/A |
| Operating profit | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | £m | -3 | -2 | -2 | -0 | -0 | -2 | N/A | N/A |
| EPS reported | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
CRISM Therapeutics Corporation is dedicated to developing innovative drug delivery systems that enhance the effectiveness of cancer medications targeting solid tumors. Their primary offering, ChemoSeed, is designed for direct insertion into a tumor or the surgical site post-tumor removal, ensuring that therapeutic concentrations of chemotherapy agents are precisely localized to the cancerous tissue. This technology finds particular application in treating gliomas, a form of brain tumor. The company was established in 2016 and is headquartered in Road Town, British Virgin Islands.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
CRISM Therapeutics Corporation (CRTX.L)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
CRISM Therapeutics Corporation is dedicated to developing innovative drug delivery systems that enhance the effectiveness of cancer medications targeting solid tumors. Their primary offering, ChemoSeed, is designed for direct insertion into a tumor or the surgical site post-tumor removal, ensuring that therapeutic concentrations of chemotherapy agents are precisely localized to the cancerous tissue. This technology finds particular application in treating gliomas, a form of brain tumor. The company was established in 2016 and is headquartered in Road Town, British Virgin Islands.